HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Sanofi Board Forces Out CEO Chris Viehbacher Amid Lantus Woes

This article was originally published in The Tan Sheet

Executive Summary

Sanofi announced that Christopher Viehbacher has resigned as CEO after its board voted unanimously to remove him. The drama comes amid serious worries over the group’s cash cow medicine, Lantus.

You may also be interested in...



Complex CVR Will Enable Genzyme And Sanofi Shareholders To Share Potential Upside For Lemtrada

A six-part contingent value right included along with Sanofi-Aventis’ cash payment of $74 a share (about $20.1 billion) for Genzyme should enable both companies’ shareholders to share in the potential upside of Lemtrada (alemtuzumab) if it is approved as a treatment for multiple sclerosis.

Sanofi-Aventis Acquisitions Could Double OTC Sales By 2014

French drug maker Sanofi-Aventis is establishing an OTC division and plans to double revenues from nonprescription drug products within five years

Vectura Reaps Value From Pan-JAK Inhibitor For Severe Asthma

The UK’s Vectura plc is gaining value from its back catalog of novel compounds through licensing its pan-JAK inhibitor, VR588, to a US start-up, the venture capital-backed Kinaset Therapeutics.

Topics

Related Companies

UsernamePublicRestriction

Register

OM013133

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel